about
Novel (Hetero)arylalkenyl propargylamine compounds are protective in toxin-induced models of Parkinson's diseaseConformational selection of inhibitors and substrates by proteolytic enzymes: implications for drug design and polypeptide processingFunctional Characterization of D9, a Novel Deazaneplanocin A (DZNep) Analog, in Targeting Acute Myeloid Leukemia (AML)Evidence for gliotoxin-glutathione conjugate adducts.CLEVER: pipeline for designing in silico chemical libraries.Atmospheric pressure aminocarbonylation of aryl iodides using palladium nanoparticles supported on MOF-5.Structural insights into the design of small molecule inhibitors that selectively antagonize Mcl-1.Exploring aigialomycin d and its analogues as protein kinase inhibitors for cancer targets.Diallyl tartrate as a multifunctional monomer for bio-polymer synthesis.Searching for "environmentally-benign" antifouling biocides.A class of pantothenic acid analogs inhibits Plasmodium falciparum pantothenate kinase and represses the proliferation of malaria parasitesSynthesis of 3-acyltetramates by side chain manipulation and their antibacterial activity.Novel arylalkenylpropargylamines as neuroprotective, potent, and selective monoamine oxidase B inhibitors for the treatment of Parkinson's disease.Synthesis of mimics of pramanicin from pyroglutamic acid and their antibacterial activity.One size does not fit all: Challenging some dogmas and taboos in drug discovery.Clinical utility of neuroprotective agents in neurodegenerative diseases: current status of drug development for Alzheimer's, Parkinson's and Huntington's diseases, and amyotrophic lateral sclerosis.Bidentate inhibitors of protein tyrosine phosphatases.Photoinduced Isomerization and Hepatoxicities of Semaxanib, Sunitinib and Related 3-Substituted Indolin-2-ones.Systematic Evaluation of the Metabolism and Toxicity of Thiazolidinone and Imidazolidinone Heterocycles.The role of modulation of antioxidant enzyme systems in the treatment of neurodegenerative diseases.Cardiomyocyte differentiation of pluripotent stem cells with SB203580 analogues correlates with Wnt pathway CK1 inhibition independent of p38 MAPK signaling.Design, synthesis and biological evaluation of FLT3 covalent inhibitors with a resorcylic acid core.3-Deazaneplanocin A and neplanocin A analogues and their effects on apoptotic cell death.Inactivation of Human Cytochrome P450 3A4 and 3A5 by Dronedarone and N-Desbutyl Dronedarone.Euplectin and coneuplectin, new naphthopyrones from the lichen Flavoparmelia euplecta.Transparent, flexible and highly conductive ion gels from ionic liquid compatible cyclic carbonate network.Efficient formal synthesis of oseltamivir phosphate (Tamiflu) with inexpensive D-ribose as the starting material.Influx of calcium through a redox-sensitive plasma membrane channel in thymocytes causes early necrotic cell death induced by the epipolythiodioxopiperazine toxins.Friedel-Crafts acylation and metalation strategies in the synthesis of calothrixins A and B.Synthesis, electrochemistry, and bioactivity of the cyanobacterial calothrixins and related quinones.Triggering apoptosis in cancer cells with an analogue of cribrostatin 6 that elevates intracellular ROS.A one step method for the functional and property modification of DOPA based nanocoatings.Mimics of pramanicin derived from pyroglutamic acid and their antibacterial activity.Metabolism-Activated Multitargeting (MAMUT): An Innovative Multitargeting Approach to Drug Design and Development.One-Pot UV-Triggered o-Nitrobenzyl Dopamine Polymerization and Coating for Surface Antibacterial Application.An efficient synthesis of an exo-enone analogue of LL-Z1640-2 and evaluation of its protein kinase inhibitory activities.Synthesis of neplanocin A and its 3'-epimer via an intramolecular Baylis-Hillman reaction.PolyPEGA with predetermined molecular weights from enzyme-mediated radical polymerization in water.A fast and straightforward route towards the synthesis of the lissoclimide class of anti-tumour agentsInactivation of rabbit muscle creatine kinase by reversible formation of an internal disulfide bond induced by the fungal toxin gliotoxin
P50
Q27301283-7C7A6C1F-745B-4B2D-8868-118ED1498DA8Q28375801-FEBF063F-AC5E-4923-9353-0A677501C698Q28546856-E0D11009-DC14-4486-BA5E-19B2EF4F09FAQ32068215-27B7B99E-E04D-4461-A7E7-9435126738A4Q33382944-DCC54B7E-BD62-4D6E-ADA1-502BC41025B9Q33453385-A3D7DAFD-B95D-46FD-B5F5-0E6953D79439Q33531468-5BC85A3C-16EC-43C1-A71A-052FA9904184Q33598661-D03A0B43-04A6-49EE-9034-77BB24A64F95Q33599478-F8A29843-26EC-412C-93B2-5F8D8BBD0846Q33907442-08DEB0D7-110A-4864-B2F3-C0E78F32BAAEQ34123671-26385D27-2ADE-4748-B177-7E8895278623Q35090265-623F130A-9651-4ADD-ACE4-38368C6B58DDQ35550196-D3CB522E-5FE2-43C7-A5AA-1BF21996E364Q35554441-1F4998CC-713B-49A9-A148-3EB3168320BFQ35874098-991B1A8C-49FB-45D5-AC03-AFF5A8770BD6Q38022265-1DB50661-D765-41B7-B5FC-B08FEE80FC85Q38160943-CD98C8B4-0FD8-40C7-AA12-328C0204C972Q38817731-DCAEC7C7-5E22-4D83-A70E-803C1D9B0882Q38832934-13993F7D-96F4-4BB9-B1DB-311D45C131A8Q38889475-21E38974-3EB4-4B41-80EF-360C5C7C04C7Q38926649-E260A727-A778-4866-A967-E568DE299808Q38934031-28577DF1-532B-4A38-A487-6BB6F31FB9ACQ38947403-0EFD7641-9F8C-40D4-BF32-5EC8EB5EDC2AQ38951096-3140E5B9-C52B-463B-836D-5320277C1AE5Q40903534-A71B90F7-B599-4E78-8B58-9ED7B4921F76Q43159709-AE602893-D631-48E4-BF6B-10B20431BC46Q43235634-3E2ADCB2-BEC2-4F63-ADEB-C46A997E99E1Q44026925-7FAF82EA-786E-488E-B0AD-10787AC1A129Q44646373-B31EB4D3-6AB1-46F5-9FB3-C4CF66724AEFQ45060237-D37F4C79-C93C-4D07-A6D9-603717AC4C3BQ46479904-6687EC10-EB69-4A8D-A886-91C2E610D0F7Q47793997-82D5CEC0-D442-4A8F-9CA0-A76A4C2C4B7AQ48267872-2B21D233-6FFD-4ADD-BB0B-29BBEBD96119Q50920496-0961CD80-2711-4247-A25C-F38FAC1B2CC2Q51083302-812DA09D-59EA-42E9-A56D-A799D65FC850Q51656630-7068B67D-D144-4595-B6D5-E7B8D8F0EB9FQ53473689-69113099-8E12-45CC-9915-F60A9B7F22AEQ53949243-7A20A809-9CD6-46A7-A342-449F2F136D88Q57591342-B5AA11ED-63BE-4020-B0E9-75A6B1F972E9Q73825744-8E966381-C9AE-4A23-B6EF-B7E943D1F7CB
P50
description
researcher ORCID ID = 0000-0002-9199-851X
@en
name
Christina L.L. Chai
@ast
Christina L.L. Chai
@en
Christina L.L. Chai
@es
Christina L.L. Chai
@nl
type
label
Christina L.L. Chai
@ast
Christina L.L. Chai
@en
Christina L.L. Chai
@es
Christina L.L. Chai
@nl
prefLabel
Christina L.L. Chai
@ast
Christina L.L. Chai
@en
Christina L.L. Chai
@es
Christina L.L. Chai
@nl
P1153
25647371600
P21
P31
P496
0000-0002-9199-851X